Evidence map›Paper›PMID 42292773›Full record

ArticleOpen forum infectious diseases2026

First TES in Djibouti: A Critical Milestone Amid Rising Regional Threats.

Sinknesh Wolde Behaksra, Samatar Kayad Guelleh, Solomon Sisay, Yisihak Abreham Weldehana, Daniel Mussa Weyesa, Tirhas Endale, Assia Adlao Hamad, Natnael Lemessa Hundera, Dawit Hailu Alemayehu, Elias B Tafa and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sinknesh Wolde BehaksraMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Samatar Kayad GuellehProgramme National de Lutte Contre Le Paludisme, Direction des Programmes de Santé Prioritaires, Ministère de La Santé, Djibouti, Republic of  Djibouti.
Solomon SisayMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Yisihak Abreham WeldehanaMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Daniel Mussa WeyesaMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Tirhas EndaleMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Assia Adlao HamadProgramme National de Lutte Contre Le Paludisme, Direction des Programmes de Santé Prioritaires, Ministère de La Santé, Djibouti, Republic of  Djibouti.
Natnael Lemessa HunderaMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Dawit Hailu AlemayehuMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Elias B TafaMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.ORCID https://orcid.org/0009-0008-7609-2382
William LouieEPPIcenter Program, Division of HIV, ID and Global Medicine, University of California, SanFrancisco, California, USA.
Andres Aranda-DiazEPPIcenter Program, Division of HIV, ID and Global Medicine, University of California, SanFrancisco, California, USA.
Meklit ShiferawMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Matiwos Kidane AyeleMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Fikregabrail Aberra KassaMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Dagim Hailegebrel LakewMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Amanuel ShimelashMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Betelhem Akililu KebedeMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Melat AbdoMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Migbaru Keffale BezabihMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Yahya Osman MoussaClinical Biology Department, Police Health Service, Djibouti, Republic of  Djibouti.
Tesfaye Sisay TessemaDepartment of Biotechnology, Addis Ababa University, Addis Ababa, Ethiopia.ORCID https://orcid.org/0000-0002-4103-5029
Bryan GreenhouseEPPIcenter Program, Division of HIV, ID and Global Medicine, University of California, SanFrancisco, California, USA.
Abdoulilah Ahmed AbdiPresidency Health Council, Djibouti Armed Forces Health Services, Djibouti, Republic of  Djibouti.
Bouh Abdi KhairehProgramme National de Lutte Contre Le Paludisme, Direction des Programmes de Santé Prioritaires, Ministère de La Santé, Djibouti, Republic of  Djibouti.
Fitsum G TadesseMalaria and NTD Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.ORCID https://orcid.org/0000-0003-1931-1442

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Malaria control in the Horn of Africa faces growing challenges from emerging antimalarial resistance, diagnostic failures due to gene deletions, and the invasive Methods: A 28-day, single-arm TES was conducted at Arhiba Health Center in Djibouti City from 16 April 2024 to 5 May 2024, enrolling patients aged ≥6 months with uncomplicated Results: Of 88 enrolled patients, 70 completed follow-ups. The PCR-adjusted adequate clinical and parasitological response (ACPR) was 98.6% (95% CI, 96.1-100.0), with one recrudescence. Gametocytes were observed in 11.4% at baseline and persisted through day 21. HRP2-based RDT detected only 37.5% of infections compared to 100% using pLDH-based RDT, consistent with Conclusions: Artemether-lumefantrine remains effective in Djibouti; however, widespread Clinical Trials Registration: Pan African Clinical Trial Registry (PACTR202508856741773).

Indexed as

artemether-lumefantrinedrug resistancehorn of Africar622Itherapeutic efficacy

Identifiers

PMID42292773
PMCPMC13262534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.